BCL2L11 — gene · CancerIndex

Curated evidence

Clinical evidence (4)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BCL2L11 Alternative splicing1
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	4	submitted	EID9699 Primary imatinib resistance is caused by a deletion polymorphism in intron 2 (see EID 1280 and 1281). An in vitro study shows that the deletion biases BIM splicing from exon 4 to exon 3. Adding ASOs t… (full text at CIViC) PMID 29100409 · Liu et al., 2017 · Open in CIViC	civic
BCL2L11 Deletion Polymorphism3
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance

Cohorts

Alteration frequency by cohort (17)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved17 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor (TCGA GDC, 2025) ucs_tcga_gdc	Uterine Malignant Mixed Mesodermal (Mullerian) Tumor	Ssm	3	57

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
· Nat Med · 2012 · PMID 22426421 · validated civic_curation pubmed